‘DURVIT’: a phase-I trial of single low-dose durvalumab (Medi4736) IntraTumourally injected in cervical cancer: safety, toxicity and effect on the primary tumour- and lymph node mi...

por Rotman, J., Mom, C. H., Jordanova, E. S., de Gruijl, T. D., Kenter, G. G.
Publicado 2018

HLA-G Expression Is an Independent Predictor for Improved Survival in High Grade Ovarian Carcinomas

por Rutten, M. J., Dijk, F., Savci-Heijink, C. D., Buist, M. R., Kenter, G. G., van de Vijver, M. J., Jordanova, E. S.
Publicado 2014

CXCR7 expression is associated with disease-free and disease-specific survival in cervical cancer patients

por Schrevel, M, Karim, R, ter Haar, N T, van der Burg, S H, Trimbos, J B M Z, Fleuren, G J, Gorter, A, Jordanova, E S
Publicado 2012

Tbet-positive regulatory T cells accumulate in oropharyngeal cancers with ongoing tumor-specific type 1 T cell responses

por Santegoets, S. J., Duurland, C. L., Jordanova, E. S., van Ham, J. J., Ehsan, I., van Egmond, S. L., Welters, M. J. P., van der Burg, S. H.
Publicado 2019

Efficacy of PD-1 blockade in cervical cancer is related to a CD8(+)FoxP3(+)CD25(+) T-cell subset with operational effector functions despite high immune checkpoint levels

por Heeren, A. M., Rotman, J., Stam, A. G. M., Pocorni, N., Gassama, A. A., Samuels, S., Bleeker, M. C. G., Mom, C. H., Zijlmans, H. J. M. A. A., Kenter, G. G., Jordanova, E. S., de Gruijl, T. D.
Publicado 2019

Pre-treatment tumor-infiltrating T cells influence response to neoadjuvant chemoradiotherapy in esophageal adenocarcinoma

por Goedegebuure, R.S.A., Harrasser, M., de Klerk, L.K., van Schooten, T.S., van Grieken, N.C.T., Eken, M., Grifhorst, M.S., Pocorni, N., Jordanova, E.S., van Berge Henegouwen, M.I., Pouw, R.E., Verheul, H.M.W., van der Vliet, J.J., van Laarhoven, H.W.M., Thijssen, V.L.J.L, Bass, A.J., De Gruijl, T.D., Derks, S.
Publicado 2021